Author/Editor		Reberšek, Martina; Boc, Marko; Cerkovnik, Petra; Benedik, Jernej; Hlebanja, Zvezdana; Volk, Neva; Novaković, Srdjan; Ocvirk, Janja
Title		Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis
Translated title		Učinkovitost sistemsekega zdravljenja prvega reda pri bolnikih z razsejanim rakom debelega črevesa in danke v povezavi z BRAF in različnimi KRAS mutacijami
Type		članek
Source		Radiol Oncol
Vol. and No.		Letnik 45, št. 4
Publication year		2011
Volume		str. 285-91
Language		eng
Abstract		Background. KRAS mutation status in codons 12 and 13 is recognized as a predictive factor for resistance to anti- EGFR monoclonal antibodies. Despite having a wild type KRAS (wt-KRAS), not all patients with wt-KRAS respond toanti-EGFR antibody treatment. Additional mechanisms of resistance may activate mutations of the other main EGFR effectors pathway. Consequently, other molecular markers in colorectal cancer are needed to be evaluated to predict the response to therapy.Patients and methods. In this retrospective study, objective responses (OR), time to progression (TTP), overall survival (OS) were analyzed in 176 metastatic colorectal cancer (mCRC) patients treated with first-line chemotherapy in combination with monoclonal antibodies in respect of KRAS status in codons 12 and 13 and BRAF mutational status. Results. The KRAS mutations were found in 63 patients (35.8 ), the KRAS mutation in codon 12 in 53 patients (30.1%)and the KRAS mutation in codon 13 in 10 patients (5.7%). The BRAF V600E mutation was detected in 13 of 176 patients (7.4%). In the subgroup of mCRC patients having wt-KRAS and wild type BRAF (wt-BRAF), the objective response rates were higher (OR 54.0%, CR 14.7%, PR 39.3%) than in the patients with wt-KRAS and mt-BRAF (OR 38.5%,CR 15.4%, PR 23.1%), the difference was not statistically significant (p= 0.378). Median OS in patients with wt-KRAS wt-BRAF, and in patients with wt-KRAS mt-BRAF, was 107.4 months and 45 months, respectively. The difference was statistically significant (p= 0.042). TTP in patients with wt-KRAS wt-BRAF, and in patients with wt-KRAS mt-BRAF, was 16 months and 12 months, respectively. (Abstract truncated at 2000 characters)
Descriptors		COLORECTAL NEOPLASMS NEOPLASM METASTASIS MUTATION ANTIBODIES, MONOCLONAL GENES, ERBB-1 GENES, RAS SURVIVAL ANALYSIS RETROSPECTIVE STUDIES